Incidence of chemotherapy-induced nausea and emesis after modern antiemetics

Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics

Chemotherapy-induced nausea and vomiting (CINV) is one of the most common symptoms feared by patients, but may be prevented or lessened with appropriate medications. Several antiemetic options exist to manage CINV. Corticosteroids, serotonin receptor antagonists, and neurokinin receptor antagonists are the classes most commonly used in the prevention of CINV. There are many alternative drug cla...

The Effect of Semi-Upright Position on Incidence and Intensity of Chemotherapy-Induced Nausea and Vomiting

Neuropharmacology of chemotherapy-induced emesis.

Oncology Patient Evidence-Based Notes (OPEN): antiemetics for chemotherapy-induced nausea and vomiting.

Since the 1990s, new antiemetic agents have significantly reduced the incidence of nausea and vomiting associated with chemotherapy. Specifically, these agents are the serotonin receptor antagonists and consist of dolasetron (Anzamet, Aventis Pharmaceuticals, Bridgewater, NJ), granisetron (Kytril, Roche Pharmaceuticals, Nutley, NJ), ondansetron (Zofran, GlaxoSmithKline, Research Triangle Park, ...

Management of chemotherapy induced emesis

Important progress has been achieved in the last few years in the prevention of chemotherapy-induced nausea and vomiting thanks to the introduction in clinical practice first of the 5-HT3 antagonists and of the NK1 antagonists more recently. To prevent acute emesis induced by cisplatin/moderately emetogenic chemotherapy, a combination of aprepitant plus a 5-HT3 antagonist and dexamethasone/a 5-...